Related Links

Go Back

SNM Guidelines in Oncology

Links are provided here to some Society of Nuclear Medicine (SNM) Practice Management - Procedure Guidelines. The procedure guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs.

They are categorized in clinical applications. Please follow the links below to the desired applications. 

The purpose of this guideline is to assist nuclear medicine practitioners in evaluating patients for therapy with 131I (sodium iodide) for benign or malignant conditions of the thyroid gland, performing this treatment, understanding and evaluating the sequelae of therapy, and reporting the results of therapy.


The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of 18-fluoro-2-deoxyglucose (FDG) imaging in the evaluation of patients with suspected malignant disease,for the staging of malignant disease, or for the monitoring of therapy.


The purpose of these guidelines is to assist physicians in recommending, performing, interpreting, and reporting the results of 18-F-FDG PET/CT for oncologic imaging of adult and pediatric patients. This Procedure Guideline pertains only to combined PET/CT devices.


The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of 99mTc-sestamibi breast scintigraphy (mammoscintigraphy, scintimammography) includes planar and/or single-photon emission computed tomography (SPECT).


The intention of this guideline is to assist breast imaging practitioners in patient selection for, performance, interpretation, and reporting of 99mTc-sestamibi breast-specific gamma imaging (BSGI).


The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of lymphoscintigraphy for identifying sentinel lymph nodes for excisional biopsy in patients with melanoma and the use of the intraoperative gamma probe in the operating room.


The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of gallium-67 citrate imaging in the evaluation of patients with malignant disease.


The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of somatostatin receptor scintigraphy with In-111 pentetreotide.


The purpose of this guideline is to assist nuclear medicine practitioners in evaluating patients who
might be candidates for 32P-sodium phosphate, 89Srchloride, or 153Sm-lexidronam (153Sm-EDTMP) radiopharmaceutical treatment of bone pain due resulting from osteoblastic metastases, to provide information for performing this treatment, and to assist in understanding the sequelae of therapy.


The purpose of this Procedure Guideline is to assist physicians in recommending, performing, interpreting, and reporting the results of SPECT/CT for imaging of adult and pediatric patients. Although techniques for registration and fusion of images obtained from separate SPECT and CT scanners have been available for several years, the advantages of having SPECT and CT integrated into a single device have resulted in the development of this technology in the United States and elsewhere in the world. This Procedure Guideline pertains only to combined SPECT/CT devices.